Harvard Bioscience Showcases New Innovations at Safety Pharmacology Society Event
Harvard Bioscience, Inc. (NASDAQ: HBIO) is gearing up to present its latest innovations at the Safety Pharmacology Society Annual Meeting. This multi-day event will take place in San Diego, where the forefront of life sciences will be highlighted through groundbreaking products and technologies.
DSI™ Ponemah™ Data Management Platform Integration
The Ponemah™ platform stands out as a top-tier tool tailored for managing data from various preclinical studies. It adheres to stringent GLP standards and works effortlessly with DSI's SoHo™ implantable telemetry and VivaMARS™ behavior monitoring systems. This cutting-edge solution streamlines the collection and processing of extensive in-vivo data, linking preclinical studies with innovative in-vitro testing techniques.
The Impact of Machine Learning
Additionally, Ponemah is paving the way for the future incorporation of sophisticated machine learning algorithms. This advancement seeks to transform how large and complex data sets generated during research are analyzed.
Advancements in SoHo™ Implantable Telemetry
The newly launched SoHo telemetry system is quickly becoming a favorite among leading researchers in the preclinical field. With its compact design, it supports the examination of various small animal models while promoting natural shared housing conditions. These enhancements, along with improved power management features, extend the duration of longitudinal studies significantly.
Boosting Efficiency
By integrating with the Ponemah platform, the telemetry system simplifies the data collection and reporting process. This cohesive strategy not only reduces operational costs but also greatly improves testing throughput.
Introducing the VivaMARS™ Activity Monitoring System
Another highlight of the meeting will be the VivaMARS system, a robust platform designed for high-throughput behavioral assessments in neuropharmacology safety and toxicology research. When combined with Ponemah, VivaMARS provides a comprehensive and compliant solution tailored for Contract Research Organizations (CROs) and pharmaceutical companies.
Presenting Initial Results
During the Safety Pharmacology event, early findings featuring the VivaMARS system will be shared. This system represents a significant leap in automated behavioral testing, confirming its readiness for use across various research stages.
Spotlight on the Mesh MEA™ Organoid Platform
The company will also feature its Mesh MEA™ platform, greatly enhancing organoid research. This platform enables researchers to gather precise electrophysiological data from live organoids in real-time, set to transform applications in safety pharmacology and toxicology.
Current Research and Future Possibilities
At the moment, the Mesh MEA platform is undergoing evaluations at specialized research sites, with full production expected soon. Its ability to efficiently screen in-vitro samples is opening new pathways for more accurate assessments while minimizing the reliance on animal models.
Commitment to Advancing New Therapies
Jim Green, the Chairman and CEO of Harvard Bioscience, expressed his enthusiasm about the company's achievements at the SPS Conference, particularly with the initial production sales of the SoHo implants. The company is working closely with premier research organizations to enhance its systems and ensure they are effectively integrated into current practices.
Find Harvard Bioscience at the Annual Meeting
Harvard Bioscience will have its solutions on display at booth 501 during the Safety Pharmacology Society Annual Meeting, offering hands-on demonstrations and engaging discussions with attendees from various industry sectors.
About Harvard Bioscience
Harvard Bioscience, Inc. is committed to advancing breakthroughs in life sciences through its innovative products and technologies. They serve a diverse range of clients, from academic institutions to leading pharmaceutical companies, managing operations globally, including regions in North America, Europe, and China.
Frequently Asked Questions
What is the focus of Harvard Bioscience's presentation at the SPS Annual Meeting?
The company will showcase its latest innovations in telemetry systems, data management platforms, and applications in organoid research.
How does the Ponemah platform integrate with other systems?
Ponemah integrates smoothly with DSI's SoHo telemetry and VivaMARS systems, delivering a comprehensive data management solution.
What are the key features of the SoHo telemetry system?
The SoHo telemetry system boasts a compact design and improved power management, allowing for extended studies.
What innovations does the VivaMARS system provide?
VivaMARS supports high-throughput behavioral testing and integrates effectively with the Ponemah platform for detailed data analysis.
Who can benefit from Harvard Bioscience products?
Researchers, pharmaceutical companies, and academic institutions can all take advantage of the innovative solutions provided by Harvard Bioscience for their studies.
